PALO ALTO, Calif., Jan. 20, 2020 /PRNewswire/ -- Varian (NYSE:
VAR) today announced it has appointed Dr. Ricky Sharma, to vice president of Clinical
Affairs. In this role he will be leading medical research,
translational science and clinical trials for Varian's growing
oncology business. Dr. Sharma will report directly to
Dee Khuntia, MD, chief medical
officer and senior vice president of Medical Affairs.
A pioneer in internal radiotherapy and chemotherapy treatments
for patients with liver metastases, Dr. Sharma transformed liver
cancer care by providing evidence-based data to drive cancer
treatment options. Dr. Sharma's vision of multidisciplinary care
includes combining radiation therapies, physical therapies (thermal
ablation, cryotherapy, embolics), and pharmacologic tools
(drug-eluting beads, immunological agents, chemotherapeutic agents)
to deliver personalized care for every patient.
Dr. Sharma has personally served as the global chief
investigator in 15 phase I, II or III clinical trials in the fields
of radiation, medical and interventional oncology, including
multi-center, pivotal randomized controlled trials testing new
drug-radiotherapy combinations which have enrolled over 2,000
cancer patients. He is a Fellow of the Royal College of Physicians
and the Royal College of Radiologists and he has published over 200
articles in scientific journals.
Prior to joining Varian, Dr. Sharma was the Chair of Radiation
Oncology at University College London,
UK, where he will continue as an honorary clinical
professor. He is also a visiting professor at several universities
in other countries.
"Dr. Sharma is an international authority on the multi-modality
treatment of cancer with precision radiotherapy as well as on the
translation of radiobiology from the laboratory to the clinic,"
said Dr. Khuntia. "His experience of leading practice-changing
international clinical trials and his well-established track record
in taking cancer care innovations from the scientific laboratory to
patients in the clinic will be critical in demonstrating a strong
evidence base for Varian's new technologies in the fight against
cancer."
"It is an honor to join Varian to spearhead its ongoing efforts
to provide the best treatment to patients anywhere in the world,"
said Prof. Dr. Sharma. "I am proud to be part of a company
that innovates, supports and simplifies cancer-fighting
solutions everywhere to create a world without fear of cancer."
Dr. Sharma obtained his medical degree and an M.A. from the
University of Cambridge, UK, and
subsequently a PhD from the MRC Toxicology Unit, University of
Leicester. Dr. Sharma was an
Associate Professor at the University of
Oxford, UK, where he was a consultant in Clinical
Oncology. He has a clinical practice in chemotherapy and
radiotherapy, which he will continue.
About Varian
At Varian, we envision a world without
fear of cancer. For more than 70 years, we have developed, built
and delivered innovative cancer care technologies and solutions for
our clinical partners around the globe to help them treat millions
of patients each year. With an Intelligent Cancer Care approach, we
are harnessing advanced technologies like artificial intelligence,
machine learning and data analytics to enhance cancer treatment and
expand access to care. Our 10,000 employees across 70 locations
keep the patient and our clinical partners at the center of our
thinking as we power new victories in cancer care. Because, for
cancer patients everywhere, their fight is our fight. For more
information, visit http://www.varian.com and follow
@VarianMedSys on Twitter.
Press Contact
Mark Plungy
Director, Global Public Relations
+1 (650) 424-5630
mark.plungy@varian.com
Investor Relations Contact
Anshul Maheshwari
Vice President, Investor Relations
+1 (650) 424-5631
investors@varian.com
View original
content:http://www.prnewswire.com/news-releases/varian-appoints-prof-dr-ricky-sharma-vp-of-clinical-affairs-300987703.html
SOURCE Varian